• FirefoxUpgrade to the new Firefox »
  •  Dow Down2.00% Nasdaq Down1.77%

    More On TKM.TO



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Tekmira Pharmaceuticals Corporation (TKM.TO)

    31.90 Up 0.10(0.31%) 11:44AM EST
    Add to Portfolio
    ProfileGet Profile for:
    Tekmira Pharmaceuticals Corporation
    100-8900 Glenlyon Parkway
    Burnaby, BC V5J 5J8
    Canada - Map
    Phone: 604-419-3200
    Fax: 604-419-3201
    Website: http://www.tekmirapharm.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Its pipeline products include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials, which targets polo-like kinase 1, a protein involved in tumor cell proliferation and a validated oncology target; and TKM-HBV, which is in Phase I clinical trial to eliminate surface antigen expression in the chronically infected patients. The company is also involved in developing TKM-Ebola, an anti-ebola viral therapeutic that is in Phase I clinical trial; and TKM-Marburg to treat Marburg infections. In addition, its preclinical product candidate includes TKM-ALDH2 for the treatment of alcohol use disorder. The company has strategic alliances with Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Monsanto Company; Marina Biotech, Inc./Arcturus Therapeutics, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and U.S. National Institutes of Health. Tekmira Pharmaceuticals Corporation is headquartered in Burnaby, Canada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Tekmira Pharmaceuticals Corporation

    Key Executives 
    Dr. Mark J. Murray Ph.D., 66
    Chief Exec. Officer, Pres and Director
    Mr. Bruce G. Cousins C.A., CPA, 54
    Chief Financial Officer, Principal Accounting Officer and Exec. VP
    Dr. Peter Lutwyche Ph.D.,
    Sr. VP of Pharmaceutical Devel.
    Dr. Michael J. Abrams Ph.D., 59
    Chief Discovery Officer and Exec. VP
    Dr. Mark M. Kowalski M.D., Ph.D., 60
    Chief Medical Officer and Sr. VP
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.